Torsdag 12 Mars | 15:19:35 Europe / Stockholm

Kalender

Est. tid*
2026-11-11 08:30 Kvartalsrapport 2026-Q3
2026-08-26 08:30 Kvartalsrapport 2026-Q2
2026-05-28 N/A X-dag ordinarie utdelning QLIFE 0.00 SEK
2026-05-27 N/A Årsstämma
2026-05-13 08:30 Kvartalsrapport 2026-Q1
2026-02-26 - Extra Bolagsstämma 2026
2026-02-11 - Bokslutskommuniké 2025
2025-11-12 - Kvartalsrapport 2025-Q3
2025-08-27 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2025-05-28 - Årsstämma
2025-05-20 - Kvartalsrapport 2025-Q1
2025-03-21 - Extra Bolagsstämma 2025
2025-02-12 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-07-30 - Split QLIFE 2000:1
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-08 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2023
2023-11-13 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 - Årsstämma
2023-03-24 - Extra Bolagsstämma 2022
2023-02-16 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-08 - Kvartalsrapport 2021-Q3
2021-08-16 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret beläget i Helsingborg.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-02-25 08:30:00

Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, today announces that the previously communicated pilot project for blood testing in pharmacies has now been launched. The pilot is being initiated in selected pharmacies in the Nordic region and represents an important step in Qlife's strategy to expand into decentralized healthcare settings.

The pilot is designed to evaluate the integration of Qlife's and Hipro's point-of-care testing solutions within the pharmacy environment, including workflow, training, and patient uptake. The objective is to assess operational scalability and commercial potential ahead of broader implementation.

"We are pleased to now have the pharmacy pilot live with strong support from the participating pharmacies. This marks the transition to real-world execution in this segment and provides valuable insight into how blood testing can be integrated into everyday pharmacy practice. We see strong interest in decentralized testing solutions and look forward to evaluating the results of the pilot," says Thomas Warthoe, CEO of Qlife

The pilot follows Qlife's previously announced preparations to introduce blood testing services in pharmacies across Denmark, Sweden and the UK. The initiative is aligned with broader healthcare trends aimed at increasing accessibility, reducing pressure on primary care, and enabling faster patient decision-making.

For more information, please contact:

Thomas Warthoe, Chief Executive Officer (CEO)

Phn: +45 21 63 35 34

E-mail: tw@egoo.health

Qlife is a Swedish company based in Göteborg, which develops and markets an innovative medical technology platform, Egoo.Health ("Egoo"), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company's Certified Adviser. For additional information, please visit www.qlifeholding.com.